Blueprint Medicines Corporation (BPMC): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPMC POWR Grades
- Value is the dimension where BPMC ranks best; there it ranks ahead of 96.14% of US stocks.
- BPMC's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- BPMC's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).
BPMC Stock Summary
- BPMC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 12.46% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Blueprint Medicines Corp is reporting a growth rate of -182.95%; that's higher than merely 11.3% of US stocks.
- Revenue growth over the past 12 months for Blueprint Medicines Corp comes in at 1,024.61%, a number that bests 99% of the US stocks we're tracking.
- Stocks that are quantitatively similar to BPMC, based on their financial statements, market capitalization, and price volatility, are CLGN, KIN, SGBX, GBT, and QURE.
- BPMC's SEC filings can be seen here. And to visit Blueprint Medicines Corp's official web site, go to www.blueprintmedicines.com.
BPMC Stock Price Chart Interactive Chart >
BPMC Price/Volume Stats
|Current price||$84.48||52-week high||$125.61|
|Prev. close||$85.56||52-week low||$66.20|
|Day high||$87.98||Avg. volume||441,772|
|50-day MA||$92.30||Dividend yield||N/A|
|200-day MA||$97.49||Market Cap||4.93B|
Blueprint Medicines Corporation (BPMC) Company Bio
Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.
BPMC Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
We started the process of determining a valid price forecast for Blueprint Medicines Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Blueprint Medicines Corp ranked in the 36th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. As for the metrics that stood out in our discounted cash flow analysis of Blueprint Medicines Corp, consider:
- Blueprint Medicines Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 24.08% of US stocks with positive free cash flow.
- Blueprint Medicines Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -72.58. This coverage rate is greater than that of only 1.94% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- Relative to other stocks in its sector (Healthcare), Blueprint Medicines Corp has a reliance on debt greater than just 11.48% of them.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
BPMC Latest News Stream
|Loading, please wait...|
BPMC Latest Social Stream
View Full BPMC Social Stream
Latest BPMC News From Around the Web
Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). For the first time, advanced SM patients can now receive a targeted therapy designed to potently and selectively inhibit D816V mutant KIT, the central
Those invested in the precision therapy company Blueprint Medicines Corp. (BPMC) are highly anticipating its upcoming PDUFA date (aka FDA action date) for a new drug called Avapritinib. If the June 16 action date is a success, the company will look to launch its advanced systemic mastocytosis (AdvSM) drug to market in 2Q21. (See BPMC stock analysis on TipRanks) Andrew Fein of H.C. Wainwright & Co. wrote that the launch will be “just the beginning” for Blueprint, as more research and testing will be completed in the future for treatments of the non-advanced version of the disease. Fein reiterated the stock as a Buy and assigned a price target of $135, reflecting a potential 12-month upside of 59.35%.
Most Shareholders Will Probably Find That The CEO Compensation For Blueprint Medicines Corporation (NASDAQ:BPMC) Is Reasonable
Under the guidance of CEO Jeff Albers, Blueprint Medicines Corporation ( NASDAQ:BPMC ) has performed reasonably well...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and provide a corporate update.
BPMC Price Returns
Continue Researching BPMCWant to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:
Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch